News

LABIOTECH || Partnership between Paradigm4 and Alnylam accelerates drug target discovery

New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.

whitepages icon x

Biocompare || Peptidomics: Methods in the search for molecular disease signatures

Peptides play important roles in human physiology. They present as intact peptides or can arise from protein degradation. Regardless of the source, peptidomics—the characterization of intact peptides in a biological sample—is fast emerging as an approach to uncover another layer in human health and disease.

whitepages icon x

datanami | Key Questions to Ask of Your Scientific Data Platform for Single Cell Analysis

The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk

whitepages icon x

Manufacturing Chemist | Multidimensional data analysis platforms: meeting new FDA calls for consistent evidence from CGT developers

Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns